MedDataX Logo

Telmisartan Tab Hypertension

NCT ID: NCT00890084

Last Updated: 2014-04-08

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2913 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the efficacy of telmisartan in hypertensive patients with high cardiovascular risk

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study

NCT00909038

Hypertension
COMPLETED

Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension

NCT00638911

Hypertension
COMPLETED

Telmisartan in Mild to Moderate Hypertensive Patients

NCT02260089

Hypertension
COMPLETED PHASE4

Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients

NCT02242851

Hypertension
COMPLETED

Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals

NCT02238262

Hypertension
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Design:

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group1

Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)

Intervention Type DRUG

Telmisartan 40mg or 80mg +/- HCTZ 12.5mg or 25mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)

Telmisartan 40mg or 80mg +/- HCTZ 12.5mg or 25mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Hypertensive patients with BP. 140/90mmHgand high and very high cardiovascular risk according to the ESH/ESC Guidelines 2007 and in whom the prescriber has taken the decision to start treatment with telmisartan 40 or 80 mg, with or without HCTZ 12.5 mg or 25 mg, in the usual way and in line with the SmPC and reimbursement criteria

Exclusion Criteria

Contra-indications as in the Summary of Product Characteristics
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502.581

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pharmacovigilance and Patient Compliance in Hypertensive Patients
NCT02200575 COMPLETED
Bioequivalence of Telmisartan/ HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II
NCT02262858 COMPLETED PHASE1
Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis
NCT02178306 COMPLETED PHASE4
Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects
NCT02176512 COMPLETED PHASE1
Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide
NCT02248129 COMPLETED
Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers
NCT02262624 COMPLETED PHASE1
Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers
NCT02262598 COMPLETED PHASE1
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
NCT00168779 COMPLETED PHASE4
Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers
NCT02262780 COMPLETED PHASE1
Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers
NCT02276391 COMPLETED PHASE1
Micardis®. Observational Study in Patients With Essential Hypertension
NCT02200094 COMPLETED
Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension
NCT02176850 COMPLETED
A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients
NCT00240448 COMPLETED PHASE4
Relative Oral Bioavailability of Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy Subjects
NCT02187523 COMPLETED PHASE1
Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
NCT00890591 COMPLETED PHASE4
Candesartan Effect in Second Stage Arterial Hypertension
NCT00621153 COMPLETED PHASE4
The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension
NCT00471003 COMPLETED
Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension
NCT00872586 COMPLETED PHASE3
Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
NCT00430508 COMPLETED PHASE3
COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland
NCT01211171 COMPLETED
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.
NCT00698646 COMPLETED PHASE4
A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R
NCT02079805 COMPLETED PHASE4
Olmesartan Medoxomil Versus Losartan in Patients With Hypertension
NCT00857285 COMPLETED PHASE3
A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy
NCT01258673 COMPLETED PHASE3
BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)
NCT00546754 COMPLETED PHASE3